Ethic Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ethic Inc’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381K	Buy	6,656 +1,143	+21%	+$62.6K	﹤0.01%	1040
2026 Q1	$311K	Buy	+5,513	New	+$321K	﹤0.01%	1026
2024 Q4	–	Sell	-6,114	Closed	-$534K	–	1157
2024 Q3	$534K	Buy	6,114 +1,402	+30%	+$117K	0.01%	747
2024 Q2	$388K	Sell	4,712 -1,402	-23%	-$117K	0.01%	830
2024 Q1	$534K	Buy	6,114 +1,182	+24%	+$106K	0.01%	746
2023 Q4	$476K	Sell	4,932 -1,021	-17%	-$90.3K	0.01%	748
2023 Q3	$527K	Buy	5,953 +2,765	+87%	+$246K	0.02%	663
2023 Q2	$276K	Sell	3,188 -403	-11%	-$37.9K	0.01%	812
2023 Q1	$349K	Buy	3,591 +495	+16%	+$51.3K	0.01%	750
2022 Q4	$320K	Buy	+3,096	New	+$291K	0.02%	697

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ethic Inc's BMRN Position: Q2 2026 in Review

Ethic Inc increased its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q2 2026, buying an estimated $62.6K and bringing the position to 6,656 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Ethic Inc first reported a position in BMRN in Q4 2022 and has held it in 10 quarters since. The position peaked at $534K in Q3 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Ethic Inc held 6,656 shares of BioMarin Pharmaceuticals worth $381K as of Q2 2026.
Ethic Inc bought 1,143 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $62.6K.
BioMarin Pharmaceuticals made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1040 holding.
Ethic Inc first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Ethic Inc's BioMarin Pharmaceuticals position peaked at $534K in Q3 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.